Targeted delivery of radioisotope or chemotherapeutic loaded prodrug-polymers after pretargeting tumors with bispecific antibody complex
Although significant progress has been achieved in cancer therapy, in the last few decades, there still remains much that is incurable. Treatment usually results in temporary effects, such as improvement in the quality of life, not complete remission.
Published: |
|
---|---|
Online Access: | http://hdl.handle.net/2047/d20001225 |
Similar Items
-
Targeted in vitro and in vivo delivery of diagnostic and chemotherapeutic agents to prostate cancer cells pre-targeted with bispecific antibody-ligand complexes
Published: () -
Effect of Small-Molecule-Binding Affinity on Tumor Uptake In Vivo: A Systematic Study Using a Pretargeted Bispecific Antibody
by: Rhoden, John J., et al.
Published: (2014) -
Selective Delivery of PEGylated Compounds to Tumors by Bispecific Antibodies
by: HSIN-YI TUNG, et al.
Published: (2015) -
Active Tumoral/Tumor Environmental Dual-Targeting by Non-Covalently Arming with Trispecific Antibodies or Dual-Bispecific Antibodies on Docetaxel-Loaded mPEGylated Nanocarriers to Enhance Chemotherapeutic Efficacy and Minimize Systemic Toxicity
by: Cheng WJ, et al.
Published: (2021-06-01) -
Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors
by: Chia-Yu Su, et al.
Published: (2018-01-01)